Page 4 - கவின் ஸ்பென்சர் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from கவின் ஸ்பென்சர். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In கவின் ஸ்பென்சர் Today - Breaking & Trending Today

Nicox Amends Bond Financing Agreement with Kreos to Provide Financial Flexibility in 2021

Nicox Amends Bond Financing Agreement with Kreos to Provide Financial Flexibility in 2021
January 29, 2021 - release at 7:30 am CET
Sophia Antipolis, France
Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that it has amended its bond financing agreement with Kreos Capital, introducing an additional one-year period of interest-only payments on the outstanding principal starting on February 1, 2021, and an extension of the overall period of the loan by 6 months to July 2024. The new one-year interest-only period is expected to provide approximately €5.5 million of additional flexibility for investment in development activities in 2021. The interest rate of the bonds remains unchanged as a result of this amendment. Nicox has granted Kreos Capital 100,000 warrants for 100,000 Nicox shares, equivalent to approximately 0.27% of the present outstanding capital of the Company. ....

New York , United States , Provence Alpes Côd Azur , France General , United Kingdom , City Of , Gavin Spencer , Pharma Bio , Kepler Cheuvreux Damien Choplain , Mary Ann Chang , Sophia Antipolis , Sophie Baumont , Michele Garufi , Cantor Fitzgerald Louise Chen , States Europe , Garnier Co Victor Floch Paris , Head Of Corporate Development , Lifesci Advisors , Eyevance Pharmaceuticals , Edison Investment Research Pooya Hemami London , Amends Bond Financing Agreement , Provide Financial Flexibility , Euronext Paris , Kreos Capital , Chief Executive Officer , French State ,

Nicox Provides Fourth Quarter 2020 Business Update and Financial Highlights

Nicox Provides Fourth Quarter 2020 Business Update and Financial Highlights
Nicox Provides Fourth Quarter 2020 Business Update and Financial Highlights
Initiated two large clinical trials: Denali, the second Phase 3 of NCX 470 in glaucoma, and Mississippi, a Phase 2b of NCX 4251 in blepharitis
Phase 3 clinical trial of ZERVIATE in allergic conjunctivitis initiated by partner Ocumension Therapeutics in China
U.S. prescriptions for VYZULTA
TM by 56% over Q3 2020
Q4 2020 net revenue of €5.8 million, full year 2020 net revenue of €8.9 million and cash of €47.8 million at December 31, 2020
January 20, 2021 - release at 7:30 am CET
Sophia Antipolis, France
Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today provided a business update and financial highlights for Q4 2020 for Nicox SA and its subsidiaries (the Nicox Group ), as well as key expected value-inflection milestones in 2021. ....

New York , United States , Provence Alpes Côd Azur , France General , Gavin Spencer , Kepler Cheuvreux Damien Choplain , Mary Ann Chang , Pharma Bio , Mont Blanc , Sophia Antipolis , Sophie Baumont , Cantor Fitzgerald Louise Chen , States Europe , Garnier Co Victor Floch Paris , Santen Pharmaceutical Co Ltd Of Japan , Nicox Group , European Patent Office , Lifesci Advisors , Head Of Corporate Development , Fera Pharmaceuticals , Eyevance Pharmaceuticals , Oppenheimer Co Hartaj Singh New York , Santen Holdings Us Inc , Provides Fourth Quarter , Ocumension Therapeutics , Euronext Paris ,

Nicox's Partner Ocumension Therapeutics Initiates ZERVIATE Phase 3 Clinical Trial in China

Nicox s Partner Ocumension Therapeutics Initiates ZERVIATE Phase 3 Clinical Trial in China
December 30, 2020 - release at 7:30 am CET
Sophia Antipolis, France
Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that its partner, Ocumension Therapeutics, has initiated a Phase 3 clinical trial in China with ZERVIATE
TM, the first and only topical ocular formulation of the antihistamine cetirizine, for the treatment of ocular itching associated with allergic conjunctivitis.
Gavin Spencer, Chief Business Officer at Nicox, said:

Our teams worked very closely to obtain the Chinese Investigative New Drug approval for this trial and we are pleased that Ocumension has been able to capitalize on that with a swift initiation of the trial. This Phase 3 trial, in addition to the data package used by the FDA for ZERVIATE in the United States, is expected to be sufficient to support a Chinese New Drug Application ....

New York , United States , Provence Alpes Côd Azur , France General , South Korea , Gavin Spencer , Pharma Bio , Kepler Cheuvreux Damien Choplain , Mary Ann Chang , Sophia Antipolis , Sophie Baumont , Cantor Fitzgerald Louise Chen , States Europe , Garnier Co Victor Floch Paris , Head Of Corporate Development , Lifesci Advisors , Eyevance Pharmaceuticals , Oppenheimer Co Hartaj Singh New York , Euronext Paris , Ocumension Therapeutics , Chief Business Officer , Chinese Investigative New Drug , Chinese New Drug , Press Release , Southeast Asian , Samil Pharmaceutical ,

Nicox's Licensee Bausch + Lomb Secures Approval of VYZULTA in Colombia – IT Business Net

Nicox's Licensee Bausch + Lomb Secures Approval of VYZULTA in Colombia – IT Business Net
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

New York , United States , Provence Alpes Côd Azur , France General , Hong Kong , Victor Floc H , Gavin Spencer , Yi Chen , Hartaj Singh , Damien Choplain , Pharma Bio , Mary Ann Chang , Sophia Antipolis , Sophie Baumont , Louise Chen , Kepler Cheuvreux , States Europe , Bausch Health Companies Inc , Lifesci Advisors , Garnier Co , Oppenheimer Co , Head Of Corporate Development , Cantor Fitzgerald , Eyevance Pharmaceuticals , Hc Wainwright Co , Licensee Bausch ,

Nicox Initiates Phase 2b Trial of NCX 4251, a Potential First-in-Class Treatment for Blepharitis – IT Business Net

Nicox Initiates Phase 2b Trial of NCX 4251, a Potential First-in-Class Treatment for Blepharitis – IT Business Net
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

New York , United States , Provence Alpes Côd Azur , France General , Victor Floc H , Gavin Spencer , Yi Chen , Hartaj Singh , Damien Choplain , Pharma Bio , Mary Ann Chang , Sophia Antipolis , Sophie Baumont , Louise Chen , Kepler Cheuvreux , States Europe , Lifesci Advisors , Garnier Co , Drug Administration , Oppenheimer Co , Head Of Corporate Development , Cantor Fitzgerald , Eyevance Pharmaceuticals , Hc Wainwright Co , Initiates Phase , Potential First In Class Treatment ,